0001193125-17-335317.txt : 20171211 0001193125-17-335317.hdr.sgml : 20171211 20171107113303 ACCESSION NUMBER: 0001193125-17-335317 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20171107 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Erytech Pharma S.A. CENTRAL INDEX KEY: 0001624422 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: I0 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 60 AVENUE ROCKEFELLER CITY: LYON STATE: I0 ZIP: 69008 BUSINESS PHONE: 011-33-4-78-74-44-38 MAIL ADDRESS: STREET 1: 60 AVENUE ROCKEFELLER CITY: LYON STATE: I0 ZIP: 69008 FORMER COMPANY: FORMER CONFORMED NAME: Erytech Pharma DATE OF NAME CHANGE: 20141106 CORRESP 1 filename1.htm CORRESP

November 7, 2017

VIA EDGAR

U.S. Securities and Exchange Commission

Division of Corporation Finance

Mail Stop 3561

100 F Street, N.E.

Washington, D.C. 20549

 

Attn: J. Nolan McWilliams
     Donald E. Field
     Aamira Chaudhry
     Jean Yu

 

  Re: ERYTECH Pharma S.A.
       Registration Statement on Form F-1
       File No. 333-220867
       Request for Acceleration

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, the undersigned, as the representatives of the prospective underwriters of the above issue, hereby join in the request of ERYTECH Pharma S.A. (the “Company”) that the effectiveness of the Registration Statement on Form F-1 (File No. 333-220867) be accelerated so that the Registration Statement will become effective at 11:30 A.M. Eastern Time on November 9, 2017, or as soon thereafter as practicable.

Pursuant to Rule 460 under the Securities Act of 1933, as amended, and in connection with the foregoing, please note that the underwriters have distributed approximately 480 copies of the preliminary prospectus dated November 6, 2017, between November 6, 2017 and the date hereof, to prospective underwriters, institutional investors, dealers and others.

The undersigned, as the representatives of the prospective underwriters of the above issue, hereby represent on behalf of the underwriters that the underwriters are acting in compliance and will act in compliance with the provisions of Rule 15c2-8 promulgated under the Securities Exchange Act of 1934, as amended, in connection with the above proposed offering.

[Remainder of Page Intentionally Left Blank; Signature Page Follows]


Very truly yours,

 

By: JEFFERIES LLC
By:   /s/ Gil Bar-Nahum

Name:

Title:

 

Gil Bar-Nahum

Managing Director

 

 

By: COWEN AND COMPANY, LLC
By:   /s/ E. James Streator, III

Name

Title:

 

E. James Streator, III

Managing Director

 

 

[Signature Page to Acceleration Request]

 


By: ODDO BHF SCA
By:   /s/ Christophe Tadié

Name:

Title:

 

Christophe Tadié

Gérant

 

 

[Signature Page to Acceleration Request]

 


BY: JEFFERIES INTERNATIONAL LIMITED
By:   /s/ Gil Bar-Nahum

Name:

Title:

 

Gil Bar-Nahum

Managing Director

 

 

[Signature Page to Acceleration Request]